aspirin has been researched along with Precancerous Conditions in 43 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Precancerous Conditions: Pathological conditions that tend eventually to become malignant.
| Excerpt | Relevance | Reference |
|---|---|---|
| "and aims: Aspirin and other non-steroidal anti-inflammatory drugs have been shown to reduce the risk of colorectal cancer (CRC)." | 7.72 | Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancer. ( Bernheim, J; Buklan, G; Freund, HR; Grankin, M; Klein, E; Neufeld, D; Nissan, A; Shpitz, B, 2003) |
| " We evaluated the effects of aspirin on genetic/epigenetic alterations in precancerous conditions, i." | 3.85 | Effects of long-term aspirin use on molecular alterations in precancerous gastric mucosa in patients with and without gastric cancer. ( Das, KM; Fukui, H; Hara, K; Ito, C; Kondo, T; Kono, T; Michigami, Y; Miwa, H; Morimoto, T; Oshima, T; Tomita, T; Tozawa, K; Watari, J; Yamasaki, T, 2017) |
| "Although evidence suggests that aspirin and celecoxib may reduce the risk of esophageal adenocarcinoma (EAC) in patients with Barrett's esophagus (BE), these drugs can also cause harmful side effects." | 3.74 | Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus. ( Broughton, DE; Gazelle, GS; Hur, C; Nishioka, NS; Ozanne, E; Yachimski, P, 2008) |
| "and aims: Aspirin and other non-steroidal anti-inflammatory drugs have been shown to reduce the risk of colorectal cancer (CRC)." | 3.72 | Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancer. ( Bernheim, J; Buklan, G; Freund, HR; Grankin, M; Klein, E; Neufeld, D; Nissan, A; Shpitz, B, 2003) |
| "Effects of inhibitors of arachidonic acid (AA) metabolism on the development of fatty liver, cirrhosis, glutathione-S-transferase placental form (GST-P)-positive nodules and the generation of 8-hydroxydeoxyguanosine (8-OHdG) and thiobarbituric acid-reactive substances (TBARS), caused by a choline-deficient, L-amino acid-defined (CDAA) diet, were examined in male Fischer 344 rats by feeding CDAA diets supplemented with the inhibitors for 12 and 30 weeks." | 3.69 | Inhibition by acetylsalicylic acid, a cyclo-oxygenase inhibitor, and p-bromophenacylbromide, a phospholipase A2 inhibitor, of both cirrhosis and enzyme-altered nodules caused by a choline-deficient, L-amino acid-defined diet in rats. ( Denda, A; Endoh, T; Horiguchi, K; Kobayashi, E; Konishi, Y; Nakae, D; Noguchi, O; Ogasawara, H; Sugimura, M; Tamura, K; Tang, Q; Tsujiuchi, T, 1996) |
| "Barrett's metaplasia is one of the commonest premalignant lesions in the western world following colorectal adenomas." | 2.47 | Acid reflux and oesophageal cancer. ( Jankowski, J; Nicholson, A, 2011) |
| "Colorectal cancer is the second leading cause of mortality in the United States." | 2.43 | Colorectal cancer prevention. ( Hawk, ET; Levin, B, 2005) |
| "In familial and sporadic colorectal cancer, aspirin, other nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors have been tested for their ability to reduce polyp and cancer development in clinical studies." | 2.42 | Review article: the chemoprevention of colorectal carcinoma. ( Gasche, C, 2004) |
| "Barrett esophagus is a premalignant change of the esophagus; however, malignant transformation to esophageal adenocarcinoma is rare in patients without dysplasia." | 1.72 | Barrett Esophagus: Rapid Evidence Review. ( Bryce, C; Bucaj, M; Gazda, R, 2022) |
| "Gallbladder stones (cholecystolithiasis) are the main risk factor for gallbladder cancer (GBC), a lethal biliary malignancy with poor survival rates worldwide." | 1.56 | Evaluation of the chemopreventive potentials of ezetimibe and aspirin in a novel mouse model of gallbladder preneoplasia. ( Arrese, M; Bizama, C; Espinoza, JA; Ferreccio, C; García, P; Gómez, N; González, X; Guevara, F; Kalergis, AM; Lobos-González, L; Miquel, JF; Muñoz-Durango, N; Roa, JC; Rosa, L; Saavedra, N; Villegas, J; Wichmann, IA, 2020) |
| "The risk of gastric cancer (GC) declines after Helicobacter pylori (H." | 1.51 | DNA methylation silencing of microRNA gene methylator in the precancerous background mucosa with and without gastric cancer: Analysis of the effects of H. pylori eradication and long-term aspirin use. ( Das, KM; Fukui, H; Ito, C; Miwa, H; Oshima, T; Shimoda, T; Tomita, T; Watari, J, 2019) |
| "examined Barrett's esophagus patient preferences for cancer chemoprevention with either aspirin or celecoxib." | 1.35 | Chemoprevention and Barrett's esophagus: decisions, decisions. ( Falk, GW; Jankowski, J, 2008) |
| "Aspirin may suppress tumour incidence via salicylate by enhancing apoptosis in carcinogen-initiated cells." | 1.30 | Non-steroidol anti-inflammatory drug effect on crypt cell proliferation and apoptosis during initiation of rat colon carcinogenesis. ( Barnes, CJ; Cameron, IL; Hardman, WE; Lee, M, 1998) |
| "The dose-response relationship in male F344 rats was determined for the ability of aspirin administered in the diet to prevent azoxymethane (AOM)-induced colon cancer and aberrant crypt foci (ACF) and to reduce prostaglandin E2 (PGE2) levels." | 1.30 | Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon. ( Conran, P; Hawk, EE; Kelloff, GJ; Kramer, PM; Li, H; Lubet, RA; Pereira, MA; Schut, HA; Steele, VE, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.65) | 18.7374 |
| 1990's | 10 (23.26) | 18.2507 |
| 2000's | 14 (32.56) | 29.6817 |
| 2010's | 13 (30.23) | 24.3611 |
| 2020's | 4 (9.30) | 2.80 |
| Authors | Studies |
|---|---|
| Bryce, C | 1 |
| Bucaj, M | 1 |
| Gazda, R | 1 |
| Watari, J | 2 |
| Ito, C | 2 |
| Shimoda, T | 1 |
| Tomita, T | 2 |
| Oshima, T | 2 |
| Fukui, H | 2 |
| Das, KM | 2 |
| Miwa, H | 2 |
| Song, Y | 1 |
| Zhong, X | 1 |
| Gao, P | 1 |
| Zhou, C | 1 |
| Shi, J | 1 |
| Wu, Z | 1 |
| Guo, Z | 1 |
| Wang, Z | 1 |
| Rosa, L | 1 |
| Lobos-González, L | 1 |
| Muñoz-Durango, N | 1 |
| García, P | 1 |
| Bizama, C | 1 |
| Gómez, N | 1 |
| González, X | 1 |
| Wichmann, IA | 1 |
| Saavedra, N | 1 |
| Guevara, F | 1 |
| Villegas, J | 1 |
| Arrese, M | 1 |
| Ferreccio, C | 1 |
| Kalergis, AM | 1 |
| Miquel, JF | 1 |
| Espinoza, JA | 1 |
| Roa, JC | 1 |
| Braillon, A | 1 |
| Michigami, Y | 1 |
| Hara, K | 1 |
| Yamasaki, T | 1 |
| Kondo, T | 1 |
| Kono, T | 1 |
| Tozawa, K | 1 |
| Morimoto, T | 1 |
| Christudoss, P | 2 |
| Chacko, G | 1 |
| Selvakumar, R | 2 |
| Fleming, JJ | 2 |
| Pugazhendhi, S | 1 |
| Mathew, G | 2 |
| Pulimood, AB | 1 |
| Cowie, A | 1 |
| Noble, F | 1 |
| Underwood, T | 1 |
| Falk, GW | 1 |
| Jankowski, J | 4 |
| Hur, C | 1 |
| Broughton, DE | 1 |
| Ozanne, E | 1 |
| Yachimski, P | 1 |
| Nishioka, NS | 1 |
| Gazelle, GS | 1 |
| Gatenby, PA | 1 |
| Ramus, JR | 1 |
| Caygill, CP | 1 |
| Winslet, MC | 1 |
| Watson, A | 1 |
| Wallace, K | 1 |
| Grau, MV | 1 |
| Ahnen, D | 1 |
| Snover, DC | 1 |
| Robertson, DJ | 1 |
| Mahnke, D | 1 |
| Gui, J | 1 |
| Barry, EL | 1 |
| Summers, RW | 1 |
| McKeown-Eyssen, G | 1 |
| Haile, RW | 1 |
| Baron, JA | 1 |
| Wang, AY | 1 |
| Emura, F | 1 |
| Oda, I | 1 |
| Cox, DG | 1 |
| Kim, HS | 1 |
| Yeaton, P | 1 |
| Jankowski, JA | 1 |
| Hooper, PA | 1 |
| Wang, F | 1 |
| Lv, ZS | 1 |
| Fu, YK | 1 |
| Gravitz, L | 1 |
| Nicholson, A | 1 |
| Chaudhary, A | 1 |
| Sutaria, D | 1 |
| Huang, Y | 1 |
| Wang, J | 1 |
| Prabhu, S | 1 |
| Femia, AP | 1 |
| Salvianti, F | 1 |
| Luceri, C | 1 |
| Dolara, P | 1 |
| Salvadori, M | 1 |
| Pinzani, P | 1 |
| Caderni, G | 1 |
| Hull, M | 1 |
| Logan, RF | 1 |
| Mølck, AM | 1 |
| Poulsen, M | 1 |
| Meyer, O | 1 |
| Hawk, ET | 2 |
| Viner, JL | 1 |
| Shpitz, B | 1 |
| Klein, E | 1 |
| Buklan, G | 1 |
| Neufeld, D | 1 |
| Nissan, A | 1 |
| Freund, HR | 1 |
| Grankin, M | 1 |
| Bernheim, J | 1 |
| Gasche, C | 1 |
| Raj, A | 1 |
| Levin, B | 1 |
| Stark, LA | 1 |
| Reid, K | 1 |
| Sansom, OJ | 1 |
| Din, FV | 1 |
| Guichard, S | 1 |
| Mayer, I | 1 |
| Jodrell, DI | 1 |
| Clarke, AR | 1 |
| Dunlop, MG | 1 |
| Moral, MA | 1 |
| Khurdayan, VK | 1 |
| Bozzo, J | 1 |
| Leedham, S | 1 |
| Ye, B | 1 |
| Zhang, YX | 1 |
| Yang, F | 1 |
| Chen, HL | 1 |
| Xia, D | 1 |
| Liu, MQ | 1 |
| Lai, BT | 1 |
| Wargovich, MJ | 1 |
| Chen, CD | 1 |
| Harris, C | 1 |
| Yang, E | 1 |
| Velasco, M | 1 |
| Morgan, GP | 1 |
| Mereto, E | 1 |
| Frencia, L | 1 |
| Ghia, M | 1 |
| Tang, Q | 2 |
| Denda, A | 2 |
| Tsujiuchi, T | 2 |
| Tsutsumi, M | 1 |
| Amanuma, T | 1 |
| Murata, Y | 1 |
| Maruyama, H | 1 |
| Konishi, Y | 2 |
| Endoh, T | 1 |
| Noguchi, O | 1 |
| Kobayashi, E | 1 |
| Tamura, K | 1 |
| Horiguchi, K | 1 |
| Ogasawara, H | 1 |
| Nakae, D | 1 |
| Sugimura, M | 1 |
| Schatzkin, A | 1 |
| Lanza, E | 1 |
| Freedman, LS | 1 |
| Tangrea, J | 1 |
| Cooper, MR | 1 |
| Marshall, JR | 1 |
| Murphy, PA | 1 |
| Selby, JV | 1 |
| Shike, M | 1 |
| Schade, RR | 1 |
| Burt, RW | 1 |
| Kikendall, JW | 1 |
| Cahill, J | 1 |
| Barnes, CJ | 1 |
| Cameron, IL | 1 |
| Hardman, WE | 1 |
| Lee, M | 1 |
| Morgan, G | 1 |
| Seidensticker, F | 1 |
| Schmiegel, WH | 1 |
| Li, H | 1 |
| Schut, HA | 1 |
| Conran, P | 1 |
| Kramer, PM | 1 |
| Lubet, RA | 1 |
| Steele, VE | 1 |
| Hawk, EE | 1 |
| Kelloff, GJ | 1 |
| Pereira, MA | 1 |
| Laugier, P | 1 |
| Olmos, L | 1 |
| Steppert, A | 1 |
| Wruhs, O | 1 |
| Zandanell, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Role of in Vivo Real Time Endocytoscopy in Diagnosing Colorectal Neoplasia[NCT02324374] | 50 participants (Actual) | Interventional | 2011-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for aspirin and Precancerous Conditions
| Article | Year |
|---|---|
Aspirin and Its Potential Preventive Role in Cancer: An Umbrella Review.
Topics: Aspirin; Chemoprevention; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Meta-Ana | 2020 |
Strategies to improve outcomes in esophageal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Aspirin; Barrett Esophagus; Combined Modality Therapy; Cytodi | 2014 |
Chemoprevention in Barrett's esophagus: A pill a day?
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Diet; Esophagea | 2011 |
Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Case-Control St | 2011 |
Acid reflux and oesophageal cancer.
Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Cyclooxygenase 2; Esophageal Neoplasms; Esophagitis; Gas | 2011 |
Review article: the chemoprevention of colorectal carcinoma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Chemoprevention; Chromosoma | 2004 |
Acid suppression and chemoprevention in Barrett's oesophagus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Barrett Esophagus; Enzyme Inhib | 2004 |
Colorectal cancer prevention.
Topics: Adenomatous Polyps; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as Topic; Colo | 2005 |
Chronicles in drug discovery.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Budesonide; Cell | 2006 |
[Practice-relevant intestinal diseases: prevention of colon carcinoma].
Topics: Adenomatous Polyposis Coli; Aspirin; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyp | 1998 |
2 trials available for aspirin and Precancerous Conditions
| Article | Year |
|---|---|
Aspirin is not chemoprotective for Barrett's adenocarcinoma of the oesophagus in multicentre cohort.
Topics: Adenocarcinoma; Anticarcinogenic Agents; Aspirin; Barrett Esophagus; Cohort Studies; Demography; Eso | 2009 |
The polyp prevention trial I: rationale, design, recruitment, and baseline participant characteristics.
Topics: Adenoma; Adenomatous Polyps; Adult; Aspirin; Colonic Neoplasms; Colonic Polyps; Colonoscopy; Demogra | 1996 |
31 other studies available for aspirin and Precancerous Conditions
| Article | Year |
|---|---|
Barrett Esophagus: Rapid Evidence Review.
Topics: Adenocarcinoma; Anti-Inflammatory Agents; Aspirin; Barrett Esophagus; Esophageal Neoplasms; Humans; | 2022 |
DNA methylation silencing of microRNA gene methylator in the precancerous background mucosa with and without gastric cancer: Analysis of the effects of H. pylori eradication and long-term aspirin use.
Topics: Aged; Aspirin; Cohort Studies; DNA Methylation; Female; Gastric Mucosa; Gene Silencing; Helicobacter | 2019 |
Evaluation of the chemopreventive potentials of ezetimibe and aspirin in a novel mouse model of gallbladder preneoplasia.
Topics: Animals; Aspirin; Chemoprevention; Cholecystolithiasis; Cholesterol; Cholesterol, Dietary; Chronic D | 2020 |
RE: Low-Dose Aspirin in High-Risk Individuals With Screen-Detected Subsolid Lung Nodules: A Randomized Phase II Trial.
Topics: Aspirin; Humans; Lung; Lung Neoplasms; Multiple Pulmonary Nodules; Precancerous Conditions | 2021 |
Effects of long-term aspirin use on molecular alterations in precancerous gastric mucosa in patients with and without gastric cancer.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; CpG | 2017 |
Expression of Metallothionein after Administration of Aspirin, Vitamin C or Zinc Supplement in the DMH Induced Colon Carcinoma in Rat
Topics: 1,2-Dimethylhydrazine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Ascorbic Acid; Aspirin; Col | 2018 |
Protective role of aspirin, vitamin C, and zinc and their effects on zinc status in the DMH-induced colon carcinoma model.
Topics: 1,2-Dimethylhydrazine; Alkaline Phosphatase; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antio | 2013 |
Chemoprevention and Barrett's esophagus: decisions, decisions.
Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Cardiovascular Diseases; Celecoxib; Chemoprevention; Cyc | 2008 |
Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus.
Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Cardiovascular Diseases; Celecoxib; Chemoprevention; Cyc | 2008 |
The association of lifestyle and dietary factors with the risk for serrated polyps of the colorectum.
Topics: Age Factors; Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Aspirin; Body | 2009 |
Endoscopic submucosal dissection with electrosurgical knives in a patient on aspirin therapy (with video).
Topics: Aged; Aspirin; Dissection; Electrosurgery; Female; Gastric Mucosa; Humans; Platelet Aggregation Inhi | 2010 |
Chemoprevention: First line of defence.
Topics: Animals; Aspirin; Celecoxib; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Cyclooxygenase I | 2011 |
Chemoprevention of colon cancer in a rat carcinogenesis model using a novel nanotechnology-based combined treatment system.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; As | 2011 |
Sustained proliferation and resistance to apoptosis after a cytotoxic insult are early alterations in rat colon carcinogenesis.
Topics: 1,2-Dimethylhydrazine; Animals; Apoptosis; Aspirin; bcl-2 Homologous Antagonist-Killer Protein; Biom | 2012 |
Chemoprevention in gastroenterology.
Topics: Anticarcinogenic Agents; Aspirin; Chemoprevention; Cyclooxygenase 2 Inhibitors; Digestive System Neo | 2011 |
The combination of 1alpha,25(OH2)-vitamin D3, calcium and acetylsalicylic acid affects azoxymethane-induced aberrant crypt foci and colorectal tumours in rats.
Topics: Animals; Aspirin; Azoxymethane; Body Weight; Calcitriol; Calcium; Colorectal Neoplasms; Dose-Respons | 2002 |
Aspirin: still learning about the wonder drug.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Colorectal Neopl | 2003 |
Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; As | 2003 |
Aspirin activates the NF-kappaB signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer.
Topics: Animals; Apoptosis; Aspirin; Colorectal Neoplasms; Disease Models, Animal; Dose-Response Relationshi | 2007 |
The evidence base of proton pump inhibitor chemopreventative agents in Barrett's esophagus--the good, the bad, and the flawed!
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Barrett Esophagus; Chemoprevent | 2007 |
Induction of lung lesions in Wistar rats by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and its inhibition by aspirin and phenethyl isothiocyanate.
Topics: Animals; Anticarcinogenic Agents; Aspirin; Carcinogens; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitor | 2007 |
Inhibition of aberrant crypt growth by non-steroidal anti-inflammatory agents and differentiation agents in the rat colon.
Topics: Acetaminophen; Adenoma; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti | 1995 |
NSAIDs and the chemoprevention of colon and oesophageal cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Esophageal Neoplasms; Humans; P | 1995 |
Effect of aspirin on incidence and growth of aberrant crypt foci induced in the rat colon by 1,2-dimethylhydrazine.
Topics: 1,2-Dimethylhydrazine; Animals; Anticarcinogenic Agents; Aspirin; Body Weight; Carcinogens; Cell Div | 1994 |
Inhibitory effects of inhibitors of arachidonic acid metabolism on the evolution of rat liver preneoplastic foci into nodules and hepatocellular carcinomas with or without phenobarbital exposure.
Topics: Acetophenones; Animals; Arachidonic Acid; Aspirin; Cyclooxygenase Inhibitors; Diethylnitrosamine; Li | 1993 |
Inhibition by acetylsalicylic acid, a cyclo-oxygenase inhibitor, and p-bromophenacylbromide, a phospholipase A2 inhibitor, of both cirrhosis and enzyme-altered nodules caused by a choline-deficient, L-amino acid-defined diet in rats.
Topics: Acetophenones; Animals; Aspirin; Choline; Choline Deficiency; Cyclooxygenase Inhibitors; Fatty Liver | 1996 |
Non-steroidol anti-inflammatory drug effect on crypt cell proliferation and apoptosis during initiation of rat colon carcinogenesis.
Topics: 1,2-Dimethylhydrazine; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apopt | 1998 |
Correspondence re: R. Kim et al., Etiology of Barrett's metaplasia and esophageal adenocarcinoma. Cancer Epidemiol., Biomark. Prev., 6: 369-377, 1997.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Cell Transforma | 1998 |
Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon.
Topics: Animals; Aspirin; Azoxymethane; Colon; Colonic Neoplasms; Dinoprostone; Dose-Response Relationship, | 1999 |
[Drug induced pseudolymphoma].
Topics: Adult; Aged; Aspirin; Diagnosis, Differential; Female; Humans; Keratosis; Lymphoma; Male; Precancero | 1978 |
[Sclerosing and atrophic lichen of the penis].
Topics: Adrenal Cortex Hormones; Adult; Aspirin; Atrophy; Balanitis; Chloroquine; Circumcision, Male; Humans | 1970 |